Dr. Budde is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Division of Lymphoma
1500 East Duarte Road
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-389-3058
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2006 - 2009
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
Duke UniversityPh.D., 1995 - 2001
Tongji Medical UniversityClass of 1995
Certifications & Licensure
CA State Medical License 2012 - 2026
WA State Medical License 2006 - 2013
Awards, Honors, & Recognition
- Clinical investigator Damon runyon cancer research foundation
Clinical Trials
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Start of enrollment: 2007 Dec 01
- Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
- Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Start of enrollment: 2015 Dec 15
- Join now to see all
Publications & Presentations
PubMed
- 448 citationsPhase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chavez
Molecular Therapy. 2017-01-04 - 404 citationsCD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.Brian G. Till, Michael C. Jensen, Jinjuan Wang, Xiaojun Qian, Ajay K. Gopal
Blood. 2012-04-26 - 292 citationsNCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand
Journal of the National Comprehensive Cancer Network. 2020-03-01
Abstracts/Posters
- Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell TherapyLihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
Rituximab Key to Survival After Transplant for Mantle Cell LymphomaNovember 16th, 2017- Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell LymphomaDecember 23rd, 2023
- Join now to see all
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
